BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

701 related articles for article (PubMed ID: 31560489)

  • 21. Rasopathies - dysmorphic syndromes with short stature and risk of malignancy.
    Cizmarova M; Kostalova L; Pribilincova Z; Lasabova Z; Hlavata A; Kovacs L; Ilencikova D
    Endocr Regul; 2013 Oct; 47(4):217-22. PubMed ID: 24156711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiac manifestations and gene mutations of patients with RASopathies in Taiwan.
    Lee CL; Tan LTH; Lin HY; Hwu WL; Lee NC; Chien YH; Chuang CK; Wu MH; Wang JK; Chu SY; Lin JL; Lo FS; Su PH; Hsu CC; Ko YY; Chen MR; Chiu HC; Lin SP
    Am J Med Genet A; 2020 Feb; 182(2):357-364. PubMed ID: 31837205
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nonreentrant atrial tachycardia occurs independently of hypertrophic cardiomyopathy in RASopathy patients.
    Levin MD; Saitta SC; Gripp KW; Wenger TL; Ganesh J; Kalish JM; Epstein MR; Smith R; Czosek RJ; Ware SM; Goldenberg P; Myers A; Chatfield KC; Gillespie MJ; Zackai EH; Lin AE
    Am J Med Genet A; 2018 Aug; 176(8):1711-1722. PubMed ID: 30055033
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular and clinical profile of patients referred as Noonan or Noonan-like syndrome in Greece: a cohort of 86 patients.
    Papadopoulos G; Papadopoulou A; Kosma K; Papadimitriou A; Papaevangelou V; Kanaka-Gantenbein C; Bountouvi E; Kitsiou-Tzeli S
    Eur J Pediatr; 2022 Oct; 181(10):3691-3700. PubMed ID: 35904599
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genotype and phenotype spectrum of NRAS germline variants.
    Altmüller F; Lissewski C; Bertola D; Flex E; Stark Z; Spranger S; Baynam G; Buscarilli M; Dyack S; Gillis J; Yntema HG; Pantaleoni F; van Loon RL; MacKay S; Mina K; Schanze I; Tan TY; Walsh M; White SM; Niewisch MR; García-Miñaúr S; Plaza D; Ahmadian MR; Cavé H; Tartaglia M; Zenker M
    Eur J Hum Genet; 2017 Jun; 25(7):823-831. PubMed ID: 28594414
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Noonan, Costello and cardio-facio-cutaneous syndromes: dysregulation of the Ras-MAPK pathway.
    Tidyman WE; Rauen KA
    Expert Rev Mol Med; 2008 Dec; 10():e37. PubMed ID: 19063751
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comprehensive genetic analysis of overlapping syndromes of RAS/RAF/MEK/ERK pathway.
    Tumurkhuu M; Saitoh M; Sato A; Takahashi K; Mimaki M; Takita J; Takeshita K; Hama T; Oka A; Mizuguchi M
    Pediatr Int; 2010 Aug; 52(4):557-62. PubMed ID: 20030748
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular and clinical analysis of RAF1 in Noonan syndrome and related disorders: dephosphorylation of serine 259 as the essential mechanism for mutant activation.
    Kobayashi T; Aoki Y; Niihori T; Cavé H; Verloes A; Okamoto N; Kawame H; Fujiwara I; Takada F; Ohata T; Sakazume S; Ando T; Nakagawa N; Lapunzina P; Meneses AG; Gillessen-Kaesbach G; Wieczorek D; Kurosawa K; Mizuno S; Ohashi H; David A; Philip N; Guliyeva A; Narumi Y; Kure S; Tsuchiya S; Matsubara Y
    Hum Mutat; 2010 Mar; 31(3):284-94. PubMed ID: 20052757
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cancer spectrum and frequency among children with Noonan, Costello, and cardio-facio-cutaneous syndromes.
    Kratz CP; Franke L; Peters H; Kohlschmidt N; Kazmierczak B; Finckh U; Bier A; Eichhorn B; Blank C; Kraus C; Kohlhase J; Pauli S; Wildhardt G; Kutsche K; Auber B; Christmann A; Bachmann N; Mitter D; Cremer FW; Mayer K; Daumer-Haas C; Nevinny-Stickel-Hinzpeter C; Oeffner F; Schlüter G; Gencik M; Überlacker B; Lissewski C; Schanze I; Greene MH; Spix C; Zenker M
    Br J Cancer; 2015 Apr; 112(8):1392-7. PubMed ID: 25742478
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The face of Noonan syndrome: Does phenotype predict genotype.
    Allanson JE; Bohring A; Dörr HG; Dufke A; Gillessen-Kaesbach G; Horn D; König R; Kratz CP; Kutsche K; Pauli S; Raskin S; Rauch A; Turner A; Wieczorek D; Zenker M
    Am J Med Genet A; 2010 Aug; 152A(8):1960-6. PubMed ID: 20602484
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome.
    Nava C; Hanna N; Michot C; Pereira S; Pouvreau N; Niihori T; Aoki Y; Matsubara Y; Arveiler B; Lacombe D; Pasmant E; Parfait B; Baumann C; Héron D; Sigaudy S; Toutain A; Rio M; Goldenberg A; Leheup B; Verloes A; Cavé H
    J Med Genet; 2007 Dec; 44(12):763-71. PubMed ID: 17704260
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic and pathogenetic aspects of Noonan syndrome and related disorders.
    Zenker M
    Horm Res; 2009 Dec; 72 Suppl 2():57-63. PubMed ID: 20029240
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Atrioventricular canal defect in patients with RASopathies.
    Digilio MC; Romana Lepri F; Dentici ML; Henderson A; Baban A; Roberti MC; Capolino R; Versacci P; Surace C; Angioni A; Tartaglia M; Marino B; Dallapiccola B
    Eur J Hum Genet; 2013 Feb; 21(2):200-4. PubMed ID: 22781091
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Manifestations of Noonan Syndrome and Related Disorders.
    Breilyn MS; Mehta L
    Pediatr Endocrinol Rev; 2019 May; 16(Suppl 2):428-434. PubMed ID: 31115194
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advancing RAS/RASopathy therapies: An NCI-sponsored intramural and extramural collaboration for the study of RASopathies.
    Gross AM; Frone M; Gripp KW; Gelb BD; Schoyer L; Schill L; Stronach B; Biesecker LG; Esposito D; Hernandez ER; Legius E; Loh ML; Martin S; Morrison DK; Rauen KA; Wolters PL; Zand D; McCormick F; Savage SA; Stewart DR; Widemann BC; Yohe ME
    Am J Med Genet A; 2020 Apr; 182(4):866-876. PubMed ID: 31913576
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes.
    Kratz CP; Rapisuwon S; Reed H; Hasle H; Rosenberg PS
    Am J Med Genet C Semin Med Genet; 2011 May; 157C(2):83-9. PubMed ID: 21500339
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pain in individuals with RASopathies: Prevalence and clinical characterization in a sample of 80 affected patients.
    Leoni C; Triumbari EKA; Vollono C; Onesimo R; Podagrosi M; Giorgio V; Kuczynska E; Veltri S; Tartaglia M; Zampino G
    Am J Med Genet A; 2019 Jun; 179(6):940-947. PubMed ID: 30854769
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NRAS associated RASopathy and embryonal rhabdomyosarcoma.
    Garren B; Stephan M; Hogue JS
    Am J Med Genet A; 2020 Jan; 182(1):195-200. PubMed ID: 31697451
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An Assessment of the Therapeutic Landscape for the Treatment of Heart Disease in the RASopathies.
    Yi JS; Perla S; Bennett AM
    Cardiovasc Drugs Ther; 2023 Dec; 37(6):1193-1204. PubMed ID: 35156148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Orthopaedic conditions in Ras/MAPK related disorders.
    Reinker KA; Stevenson DA; Tsung A
    J Pediatr Orthop; 2011; 31(5):599-605. PubMed ID: 21654472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.